Omics primarily aims at the universal detection of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics) in a specific biological sample. Omics studies represent advanced and promising measurement approaches for diseases and therapeutics biomarkers discovery. Currently, integrating multiple omics datasets is a promising analytical approach to provide holistic insights to disease pathophysiology, a more practical P4 medicine (predictive, preventive, personalized, and participatory) development, and tailoring more effective therapies to individual patients.

Metabolomics is defined as the global identification and quantification of a set of small molecules, less than 1500 Daltons present in a specific biological system. While metabolites are the most functional biomolecules to reflect the phenotype proteomics provide a useful window into a range of biological processes and allow the identification of differentially expressed proteins between samples.

Together with several international collaborators we apply state of-the-art analytical approaches including targeted and untargeted metabolomics, pharmacometabolomics, lipidomics, and proteomics to provide novel insights into pathophysiological mechanisms underlying diseases, identify unique diagnostic and prognostic biomarkers, investigate drug/treatment mechanism of action and side effects at the molecular level, and identify metabolomics surrogate pattern for drug exposome to promote health outcomes at a personalized level. We warmly welcome international collaboration to our research group, where diverse perspectives and shared expertise drive innovation and excellence​